Fate Therapeutics (FATE) Revenue & Revenue Breakdown
Fate Therapeutics Revenue Highlights
Latest Revenue (Y)
$6.65M
Latest Revenue (Q)
$1.91M
Main Segment (Y)
Upfront Fee And Equity Premium
Main Geography (Y)
Upfront Fee And Equity Premium
Fate Therapeutics Revenue by Period
Fate Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2025-12-31 | $6.65M | -51.24% |
| 2024-12-31 | $13.63M | -78.55% |
| 2023-12-31 | $63.53M | -34.03% |
| 2022-12-31 | $96.30M | 72.44% |
| 2021-12-31 | $55.85M | 77.66% |
| 2020-12-31 | $31.43M | 194.33% |
| 2019-12-31 | $10.68M | 125.32% |
| 2018-12-31 | $4.74M | 15.44% |
| 2017-12-31 | $4.11M | -6.72% |
| 2016-12-31 | $4.40M | 81.08% |
| 2015-12-31 | $2.43M | 100.00% |
| 2014-12-31 | - | -100.00% |
| 2013-12-31 | $971.00K | -63.63% |
| 2012-12-31 | $2.67M | 128.21% |
| 2011-12-31 | $1.17M | - |
Fate Therapeutics generated $6.65M in revenue during NA 2025, up -51.24% compared to the previous quarter, and up 21.14% compared to the same period a year ago.
Fate Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-06-30 | $1.91M | 17.07% |
| 2025-03-31 | $1.63M | -12.42% |
| 2024-12-31 | $1.86M | -39.49% |
| 2024-09-30 | $3.07M | -54.61% |
| 2024-06-30 | $6.77M | 251.79% |
| 2024-03-31 | $1.93M | 14.86% |
| 2023-12-31 | $1.68M | -13.79% |
| 2023-09-30 | $1.94M | 108.36% |
| 2023-06-30 | $933.00K | -98.42% |
| 2023-03-31 | $58.98M | 32.97% |
| 2022-12-31 | $44.36M | 196.08% |
| 2022-09-30 | $14.98M | -19.24% |
| 2022-06-30 | $18.55M | 0.73% |
| 2022-03-31 | $18.41M | 7.89% |
| 2021-12-31 | $17.07M | 19.98% |
| 2021-09-30 | $14.22M | 6.06% |
| 2021-06-30 | $13.41M | 20.37% |
| 2021-03-31 | $11.14M | -29.91% |
| 2020-12-31 | $15.90M | 110.32% |
| 2020-09-30 | $7.56M | 38.30% |
| 2020-06-30 | $5.46M | 117.30% |
| 2020-03-31 | $2.52M | -10.24% |
| 2019-12-31 | $2.80M | 15.36% |
| 2019-09-30 | $2.43M | -13.77% |
| 2019-06-30 | $2.82M | 7.03% |
| 2019-03-31 | $2.63M | 58.46% |
| 2018-12-31 | $1.66M | 61.89% |
| 2018-09-30 | $1.03M | -0.10% |
| 2018-06-30 | $1.03M | 0.10% |
| 2018-03-31 | $1.03M | -0.10% |
| 2017-12-31 | $1.03M | 0.10% |
| 2017-09-30 | $1.03M | - |
| 2017-06-30 | $1.03M | -0.10% |
| 2017-03-31 | $1.03M | - |
| 2016-12-31 | $1.03M | 0.10% |
| 2016-09-30 | $1.03M | -0.10% |
| 2016-06-30 | $1.03M | -22.31% |
| 2016-03-31 | $1.32M | 22.86% |
| 2015-12-31 | $1.08M | 4.87% |
| 2015-09-30 | $1.03M | 211.85% |
| 2015-06-30 | $329.00K | 100.00% |
| 2015-03-31 | - | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2014-09-30 | - | 100.00% |
| 2014-06-30 | - | 100.00% |
| 2014-03-31 | - | 100.00% |
| 2013-12-31 | - | -100.00% |
| 2013-09-30 | $209.00K | -27.93% |
| 2013-06-30 | $290.00K | -38.56% |
| 2013-03-31 | $472.00K | -26.59% |
| 2012-12-31 | $643.00K | 21.78% |
| 2012-09-30 | $528.00K | - |
Fate Therapeutics generated $1.91M in revenue during Q2 2025, up 17.07% compared to the previous quarter, and up 99.06% compared to the same period a year ago.
Fate Therapeutics Revenue Breakdown
Fate Therapeutics Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 20 |
|---|---|---|---|
| Upfront Fee And Equity Premium | $31.20M | $23.10M | $6.50M |
Fate Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 23: Upfront Fee And Equity Premium (100.00%).
Quarterly Revenue by Product
| Product/Service | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Sep 21 | Jun 21 | Mar 21 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Upfront Fee And Equity Premium | - | $31.20M | $31.20M | $31.20M | $6.00M | $4.20M | $6.70M | $6.10M | $4.10M | $3.80M | $1.80M |
Fate Therapeutics Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 22 | Dec 20 |
|---|---|---|
| Upfront Fee And Equity Premium | $23.10M | $6.50M |
Fate Therapeutics's latest annual revenue breakdown by geography, as of Dec 22: Upfront Fee And Equity Premium (100.00%).
Quarterly Revenue by Country
| Country | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Sep 21 | Jun 21 | Mar 21 |
|---|---|---|---|---|---|---|---|---|
| Upfront Fee And Equity Premium | $31.20M | $6.00M | $4.20M | $6.70M | $6.10M | $4.10M | $3.80M | $1.80M |
Fate Therapeutics's latest quarterly revenue breakdown by geography, as of Mar 23: Upfront Fee And Equity Premium (100.00%).
Fate Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| ALEC | Alector | $21.05M | $3.26M |
| PRLD | Prelude Therapeutics | $12.14M | $6.50M |
| MOLN | Molecular Partners | $7.04M | $2.74M |
| FATE | Fate Therapeutics | $6.65M | $1.91M |
| CRBP | Corbus Pharmaceuticals | - | - |
| INO | Inovio Pharmaceuticals | - | - |
| NKTX | Nkarta | - | - |
| ABOS | Acumen Pharmaceuticals | - | - |
| SAVA | Cassava Sciences | - | $840.00K |
| PEPG | PepGen | - | - |
| VOR | Vor Biopharma | - | - |